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REVIEW
Unnecessary repeat requesting of tests: an audit in a
government hospital immunology laboratory
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Unnecessary repeat requesting of tests can make up a
large proportion of a laboratory’s workload. This audit set
out to establish the size of this problem and to identify the
circumstances under which these repeat requests were
made in a government tertiary hospital immunology
laboratory. The numbers of tests for immunoglobulin
measurement, common autoantibodies, and tumour
markers that were repeated over a 12 month period were
analysed by interrogating the Delphic laboratory computer
system using a management information system for raw
data enquiry protocol. Repeat requests within 12 weeks of
a previous request made up 16.78% of the total workload.
The total cost of the tests was estimated at US$ 132 151.
The waste of technician time and reagents as a result of
unnecessary repeat testing is excessive. Many of these tests
might be eliminated with the use of interventions such as
computerised reminders.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
See end of article for
authors’ affiliations
. . . . . . . . . . . . . . . . . . . . . . .
Correspondence to:
Dr J Kwok, Department of
Pathology, Queen Mary
Hospital, Pokfulam Road,
Hong Kong; kwoksy@ha.
org.hk
Accepted for publication
31 August 2004
. . . . . . . . . . . . . . . . . . . . . . .
T
he utilisation of laboratory services has
increased during the past several decades in
many health care jurisdictions around the
world.123 Studies have found up to a 17 fold
variation in the number of tests that physicians
order.4 5 In our immunology laboratory, the total
number of tests performed annually increased by
63% between 1995 and 2003.
The appropriate use of laboratory tests is
necessary for optimal patient care. Increased
laboratory use is appropriate if it allows accurate
diagnoses to be made, ideal treatment to be
identified and monitored, accurate prognoses to
be established, and patients’ hospital stays to be
shortened. Physician ordering practices have
been analysed extensively,629 and inappropriate
test ordering found to be a primary reason for
increased laboratory use.10216 Over ordering may
be the result of inexperience or lack of knowl-
edge about the appropriate use of tests,17 18
failure to check previous results, test ordering
routines that are difficult to change, or fear of
errors of omission and litigation. Moreover,
patients actively ask for tests and often attach
greater value to test results than is justified.19 20
‘‘The appropriate use of laboratory tests is
necessary for optimal patient care.’’
Performing unnecessary tests may have
adverse effects—for example, unnecessary
exposure to toxic treatments or false positive
results that may induce fear and anxiety in
patients,21 22 or may result in a cascade of further
unnecessary testing.
Laboratory tests cost the health care system
large amounts of money,23226 and their inap-
propriate use may be associated with other
inefficiencies in health care delivery. Identifying
inadequacies in the use of laboratory services
may disclose problems in other areas of health
care.
As with other areas of physician behaviour,27 28
improving the use of laboratory tests has been
difficult.29 Repeat testing is one component of
laboratory utilisation that could be modified.30 31
When a previous result is not available or the
ordering physician is unaware that the test was
performed previously,32 information technology
can present previous test results33 or give the
probability that a test will be abnormal.34
One change with great potential to affect
physician behaviour is computerised physician
order entry.35237 Alerts can be issued automati-
cally at the time of test requesting if that test was
requested recently. However, the degree to which
alerts have affected physician behaviour has
been variable.38
Many attempts have been made to change test
ordering performance and bring it into line with
existing guidelines on optimal testing. Results
have been mixed but showed that successful
strategies require a well balanced combination of
interventions.27 39242
Many serum rheumatological tests have
become available relatively recently. As a result,
some physicians are not fully aware of the
indications, sensitivity, specificity, cost, and
clinical usefulness of these tests. Several stu-
dies43246 have suggested that overuse of common
serum rheumatological tests—including anti-
nuclear antibody (ANA), rheumatoid factor
(RF), and many other autoantibody tests—leads
to unnecessary referrals and further laboratory
investigations. Failure to use these tests in a
knowledgeable and thoughtful manner can
result in diagnostic confusion and increased
costs.47
Tumour markers are widely used in the
diagnosis and management of cancer. Tumour
Abbreviations: ADNA, anti-double stranded DNA
antibodies; AENA, anti-extractable nuclear antigen
antibodies; AFP, a fetoprotein; AGPC, anti-gastric
parietal cell antibodies; AMA, antimitochondrial
antibodies; ANA, antineutrophil antibodies; ASM, anti-
smooth muscle antibodies; CEA, carcinoembryonic
antigen; PSA, prostate specific antigen; RF, rheumatoid
factor
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markers have five potential uses in patient care: screening,
diagnosis, establishing prognosis, monitoring treatment, and
detecting relapse. The value of a marker in a particular
malignancy also depends on the effectiveness of the treat-
ment available. Tumour markers have been used to screen for
occult cancer but have proved to be valuable only in selected
cancers. An extreme increase in a marker often indicates a
poor prognosis, and in some malignancies can indicate the
need for more aggressive treatment. Tumour markers have
their greatest value when used to monitor treatment in
patients with widespread cancer. Nearly all markers show
some correlation with the clinical course of disease, with
marker increases at all stages declining to normal after a
curative intervention.
‘‘One change with great potential to affect physician
behaviour is computerised physician order entry’’
Unnecessary repeat requesting of tests can make up a large
proportion of a laboratory’s workload. This audit set out to
establish the size of this problem in a government tertiary
hospital immunology laboratory. This setting has not been
studied previously and is informative because most immu-
nology tests are slow to change, so that repeat testing within
a short time serves no useful clinical purpose. We also tried to
identify the circumstances under which these repeat requests
were made because this information might suggest what
action could be taken to reduce the rate of such requests.
METHODS
Setting
The clinical immunology laboratory, in the department of
pathology, Queen Mary Hospital is a tertiary immunology
laboratory operating under the Hospital Authority of Hong
Kong. Although it primarily serves the Hong Kong West
cluster with a population of half a million people, approxi-
mately 20% of requests are from other hospital authority
hospitals. The study samples included all the laboratory
requests received from all sources during a 12 month period
from October 2001 to September 2002.
Test selection and definit ions
We analysed the use of eight tests commonly requested by
rheumatologists, the results of which are unlikely to change
greatly over short time periods, namely: IgG, IgA, and IgM
values; ANA; antimitochondria antibodies (AMA); anti-
gastric parietal cell antibodies (AGPC); anti-smooth muscle
antibodies (ASM); anti-double stranded DNA antibodies
(ADNA); anti-extractable nuclear antigen antibodies
(AENA); and RF. Immunoglobulin concentrations ordered
for the diagnosis or monitoring of myeloma were excluded.
We also analysed the following tumour marker tests, which
may be more variable over time and are useful in disease
monitoring: a fetoprotein (AFP), carcinoembryonic antigen
(CEA), CA15.3, and prostate specific antigen (PSA). All these
tests are either frequently requested, labour intensive, or high
cost. AFP ordered for the monitoring of hepatocarcinoma was
excluded. We analysed requesting patterns over a 12 month
period, identifying tests that were repeated within one day,
one week, one month, and three months of a previous
request by interrogating the Delphic laboratory computer
system using a management information system for raw data
enquiry protocol.
A literature review was performed to identify published
guidelines for performing each test, and test specific time
intervals within which a repeat test was unlikely to show
clinical change were developed (table 1). The recommended
Table 1 Test unit costs, repeat intervals, and turnaround times
Test TAT (days) Unit cost* Repeat interval References for justification of repeat interval
ANA 3 21 4 weeks 44246
AENA 4 13 4 weeks 44246
ADNA 6 11 6 weeks to 6 months 6212 weekly for active
6212 monthly for inactive46 50
RF 3 4 4 weeks Except in Sjo¨gren’s syndrome44246 51 52
AMA 8 9 4 weeks 53260
ASM 8 9 4 weeks 53260
AGPC 8 9 4 weeks 61, 62
IgG, IgA, IgM 3 7 4 weeks 63, 64
AFP 3 6.5 12 weeks 65269
CEA 3 6.5 12 weeks 65, 67, 70277
CA15.3 3 7.5 12 weeks 67, 70, 78
PSA 4 7.5 12 weeks 65, 67, 79
*In US$.
ADNA, anti-double stranded DNA antibodies; AENA, anti-extractable nuclear antigen antibodies; AFP, a fetoprotein; AGPC, anti-gastric parietal cell antibodies;
AMA, anti-mitochondrial antibodies; ANA, antinuclear antibodies; ASM, anti-smooth muscle antibodies; CEA, carcinoembryonic antigen; PSA, prostate specific
antigen; RF, rheumatoid factor; TAT, turn around time.
Table 2 Requests for common immunological tests over a 12 month period
Weeks between requests
No. of annual
requestsSame day ,1 .122 .224 .428 .8212 .12224 .24248 Total
ANA 32 77 54 129 193 161 310 136 1092 6161
AENA 15 58 29 48 73 48 106 63 440 4742
ADNA 14 107 263 644 967 667 1016 151 3829 6150
RF 23 37 28 68 85 67 116 65 489 3843
AMA 1 9 7 20 29 36 101 30 233 1427
ASM 1 12 9 20 32 37 96 37 244 1312
AGPC 1 4 3 0 3 1 2 1 15 501
IgG, IgA, IgM 39 251 271 603 699 339 519 168 2889 7059
ADNA, anti-double stranded DNA antibodies; AENA, anti-extractable nuclear antigen antibodies; AGPC, anti-gastric parietal cell antibodies; AMA, anti-
mitochondrial antibodies; ANA, antinuclear antibodies; ASM, anti-smooth muscle antibodies; RF, rheumatoid factor.
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frequencies of checking tumour markers used in our study in
different cancers are based on practice guideline sources,
including those of the National Academy of Clinical
Biochemistry; European Group on Tumour Markers;
Standards, Options and Recommendations Project; Scottish
Intercollegiate Guideline Network; and American Joint
Committee on Cancer. Table 1 also shows the turnaround
times for our laboratory.
An unnecessary repeat test was defined as one that
followed a preceding test of the same type before the test
specific time interval had elapsed, and a redundant test as an
early repeat test that might be eliminated with little loss of
information.
ANALYSIS
For each test, the registered patient’s database records were
used to perform a list screen to identify tests that might have
been performed earlier than the test specific interval. The
patient’s records included basic demographic information for
each patient, either in the hospital or outpatient setting.
To estimate the proportion of early repeats that was
redundant for a given test, the proportion of tests that met
the early repeat criteria was determined.
To estimate the potential cost savings if all these redundant
tests were eliminated, the number of tests was multiplied by
the 2002 costs/test, which were calculated as follows:
RESULTS
In total, 9231 requests for immunoglobulin measurement,
RF, ANA, AMA, ASM, AGPC, ADNA, and AENA were
repeated during the year, making up 29.6% of the total
number of these tests performed (table 2). Repeat requests
within 12 weeks of a previous request made up 14.6% of the
total number of tests. For individual tests, the corresponding
proportions were: autoantibody screens, 12.9%; RF, 8.0%; and
immunoglobulins, 31.2% (table 3). In total, 19 102 repeat
requests were made for tumour markers (table 4). Repeat
requests made within 12 weeks of a previous request
accounted for 21.2% of the total number of requests for
these tests. For individual tumour marker tests, the
corresponding proportions were: AFP, 21.4%; CEA, 13.4%;
CA15.3, 29.6%; and PSA, 20.5% (table 5).
The total cost of tests repeated within 12 weeks of a
previous test was estimated at US$ 132 151.
Shorter time periods were also analysed. Repeat autoanti-
body tests are not indicated within a four week period,44246
yet 5.3% of autoantibody screens and 4.1% of RF tests were
repeated within this time. The total cost of tests repeated
within four weeks of a previous test was estimated at US$
29 527. Tests repeated within a two week time period
accounted for 3.2% of the total workload for the year.
Possible reasons for repeat testing were sought within the
data collected. Because more than 95% of the requests are
from Queen Mary Hospital or hospital authority hospitals,
tests performed in general practice and then repeated on
referral to hospital are minimal. In addition, only 5210% of
unnecessary repeats were because of a change of consultant
or location within the hospital. More than 90% of all repeated
tests were performed by the same consultant team in the
same location. Clearly, hospital consultants and their teams
should be the target of any intervention to change this
requesting behaviour. Feedback of individual test use data to
consultants has been shown to reduce overall request
frequency for haematology and clinical chemistry tests.10 48
Whether this results in an improvement in clinical care has
been contested,49 but with the tests we have analysed there is
no doubt that frequent repeats are unnecessary.
DISCUSSION
Pathologists are required to identify areas of potential
improvement in laboratory operation, noting tests that are
Table 3 Percentage of all repeated requests within specified time frame for common immunological tests over a 12 month
period
Same day 1 week 4 weeks 12 weeks 26 weeks 52 weeks Total*
No. of annual
requests
ANA 2.9 10 26.7 59.2 87.6 100 1092 (17.7) 6161
AENA 3.4 16.6 34.1 61.6 85.78 100 440 (9.3) 4742
ADNA 0.4 3.2 26.9 69.5 90.1 100 3829 (62.3) 6150
RF 4.7 12.3 31.9 63.0 86.7 100 489 (12.7) 3843
AMA 0.4 4.3 15.9 43.8 87.1 100 233 (16.3) 1427
ASM 0.4 5.3 17.2 45.5 84.8 100 244 (18.6) 1312
AGPC 0.6 33.3 53.3 80.0 93.3 100 15 (3) 501
IgG, IgA, IgM 1.3 10.0 40.3 76.2 94.2 100 2889 (40.9) 7059
ADNA, anti-double stranded DNA antibodies; AENA, anti-extractable nuclear antigen antibodies; AGPC, anti-gastric parietal cell antibodies; AMA, anti-
mitochondrial antibodies; ANA, antinuclear antibodies; ASM, anti-smooth muscle antibodies; RF, rheumatoid factor.
*Percentage of annual requests in parenthesis.
Table 4 Requests for tumour markers over a 12 month period
Weeks between requests
No. of annual
requestsSame day ,1 .122 .224 .428 .8212 .12224 .24248 Total
AFP 66 473 648 1159 1430 1377 3096 1968 10217 24072
CEA (colon cancer) 11 90 85 251 554 727 1590 500 3808 10875
CEA (breast cancer) 6 9 25 58 91 282 654 161 1286 5438
CA15.3 2 27 67 329 457 475 912 290 2559 4582
PSA 9 26 35 150 266 179 400 167 1232 3244
AFP, a fetoprotein; CEA, carcinoembryonic antigen; PSA, prostate specific antigen.
Unnecessary repeat requesting of tests 459
www.jclinpath.com
 on 8 November 2006 jcp.bmj.comDownloaded from 
high volume, expensive, difficult to perform, or of question-
able medical benefit. As health carers strive to reduce the cost
of an episode of care, the laboratory may, ironically, incur
additional costs by providing testing that contributes to
earlier diagnosis and better disease management, although
any consequent decrease in the length of stay in hospital will
of course be cost effective. Laboratory staff must work with
physicians and the institution to design processes that reduce
cost through decreased use and improved decision making,
and by the selection of clinically relevant, cost effective
technologies and testing protocols. To evaluate new methods
and equipment, laboratory expenses must be refined to
include workload recording of individual tests and cost
accounting of supplies, equipment, facilities, and reagents.
Guidelines are urgently needed to assist test ordering.
Inappropriate tests are costly, generate more inappropriate
tests, and affect patient care. Ultimately, it is the pathologist’s
job to help clinicians to order the right tests, at the right time,
in the right order.
Tests that are repeated too early to provide useful
information represent only a small proportion of those that
are unnecessary or of marginal yield. However, they form a
group that is relatively easy to target. In the study of Bates et
al,80 8.6% of a defined group of commonly performed
chemistry tests appeared to be redundant.
Table 6 shows some possible reasons for unnecessary
repeat testing. Test duplication may occur simply because the
requesting clinician is not aware that the test has already
been performed. This should not have been a major
justification for test repeats in our study, in which all tests
had short turnaround times, of three to eight days (table 1).
Where no result is immediately available a new test is
ordered. Computerised physician ward ordering systems have
been implemented in a variety of sites,35–37 and have been
found to improve efficiency of care.37 Such behaviour might
be modified by an interactive generic clinical request system
that gives details of tests already ordered, and may also block
the re-requesting of selected tests within a specified time
frame. Computerised reminders, delivered to the ordering
physician at the time a test is ordered, hold great potential for
reducing the number of redundant tests.35 To be most
effective, these reminders should be delivered in situations
in which there is a high likelihood that they will be followed.
Our study was performed in part to prepare for the
implementation of alerts about potentially redundant tests
in our hospital.
‘‘Ultimately, it is the pathologist’s job to help clinicians to
order the right tests, at the right time, in the right order’’
However, even computerised alerts will be ignored if
clinicians do not accept the recommendation, so our results
also have implications for physician education. Some of the
redundant tests probably resulted from a poor understanding
of the half lives of tumour markers or a lack of appreciation
of the value of repeated testing of autoantibodies. Others may
have been caused by an overemphasis on surveillance. All of
these issues may be addressed through education, and
physicians in clinical laboratories should become more
involved in bringing them to medical schools and residency
programmes, and to practising physicians.
Tumour markers and autoantibody tests should be readily
addressable with computerised reminders at the time of
ordering, unless computerised ordering systems are bypassed
in obtaining these tests. It may be appropriate to repeat
certain tests more frequently in lieu of rejected requests—for
example, to guide chemotherapy of multiple myeloma using
b2 microglobulin values rather than immunoglobulin and/or
paraprotein values.
It is complicated to assess the economic impact of the
elimination of tests identified as redundant. Assuming that a
system could prevent all such redundant tests from being
performed, and assuming no adverse impact on patient care,
total costs in our laboratory could be trimmed by about US$
132 262.5/year. These savings could be used to employ
additional staff who could contribute to the performance of
income generating activities, such as clinical trials. It is only
by reducing laboratory costs and increasing income that
resources can be freed for the development of new ‘‘cutting
edge’’ services.
Our study was performed at only one large university
hospital laboratory, so that it may not be possible to
generalise to other settings. A randomised trial is required
to determine how many of these tests can actually be
eliminated. Our projections were based on a small sample of
the performed tests that may not have been representative of
the entire range of tests. Another limitation is that clinical
changes may have occurred that were not documented in the
medical record. The tests that were analysed are those that
are frequently used and for which published guidelines or
recommendations exist. The usefulness of repeating other
tests is an area for further investigation. Finally, even for the
tests included in our study, more stringent intervals may
make sense. Our criteria for defining an early repeat were
usually more generous than those published in the literature.
For example, most autoantibody tests not used in disease
activity monitoring are never justified for repeat when
positive, but may be repeated when negative.50–62 We have
Table 5 Percentage of all repeated requests within specified time frame for tumour markers over a 12 month period
Same
day 1 week 4 weeks 12 weeks 26 weeks 52 weeks Total*
No. of annual
requests
AFP 0.6 5.3 23.0 50.4 80.8 100 10217 (42.4) 24072
CEA (colon cancer) 0.3 2.7 11.5 45.1 86.9 100 3808 (35.0) 10875
CEA (breast cancer) 0.5 1.2 7.6 36.6 87.5 100 1286 (23.6) 5438
CA15.3 0.1 1.1 16.6 53.0 88.7 100 2559 (55.8) 4582
PSA 0.7 2.8 17.9 24.0 86.4 100 1232 (38.0) 3244
AFP, a fetoprotein; CEA, carcinoembryonic antigen; PSA, prostate specific antigen.
*Percentage of annual request in parenthesis.
Table 6 Possible reasons for repeat testing
Not aware that the test has already been performed
Poor understanding of half lives of tumour markers
Lack of appreciation of the value of repeated testing of autoantibodies
Overemphasis on surveillance
Inexperience or lack of knowledge about the appropriate use of tests
Failure to check previous results
Test ordering routines that are difficult to change
Fear of errors of omission and litigation
Patients actively ask for tests
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used an interval of four weeks for these tests, whether
positive or negative, based on the half life of IgG (23 days).
‘‘Combinations of practice guidelines, modifications to the
laboratory requisition form, and funding policy changes
were associated with significant decreases in the use of
several tests’’
Interventions to improve laboratory utilisation include
feedback, physician education, laboratory requisition form
changes, policies concerning laboratory test ordering, and
financial incentives.81 Studies have concluded that educa-
tional interventions have mixed effects on laboratory test
use.29 82–84 Significant decreases in test rates were seen when
laboratory requisition forms were modified to contain fewer
test choices,85 presented tests in physiologically sensible
groups,86 87 or required ordering physicians to justify the
need for the test.88 Some studies have shown that policies
that prohibit particular tests in particular situations83 or limit
the allowable total number of investigations89 are effective in
decreasing use. However, their effect decays with time if the
intervention programme is not continued.90 Combinations of
practice guidelines, modifications to the laboratory requisi-
tion form, and funding policy changes were associated with
significant decreases in the use of several tests. The effects of
these interventions were persistent and avoided a large
number of tests, resulting in decreased costs.91
In our audit, there was no attempt to determine whether
the tests were ordered appropriately. Some of the repeated
tests may have been requested to confirm a previous
abnormal result, but this too is a practice that we would
not encourage unless the results truly conflict with the
clinical findings. In such cases, the physician should consult
the laboratory directly, in response to which senior immu-
nologists should maintain close involvement with the re-
testing procedure. Physicians should become familiar with all
the validation processes in place for ensuring accuracy of
reported test results, and laboratory scientists must be able to
provide convincing evidence that the laboratory’s results are
trustworthy.
A population based assessment is optimal for the accurate
measurement of repeat laboratory testing. This allows
laboratory use to be studied for everyone within a geogra-
phical area, rather than within a particular hospital or health
services organisation. A population based analysis allows
laboratory use to be followed even when patients transfer
between different sectors of the healthcare system, such as
from the community to the hospital. Finally, a population
based analysis produces unbiased utilisation rates because a
true denominator (that is, all the people in a particular area)
rather than a ‘‘pseudodenominator’’ (all the people who had
a laboratory test) is used. This is necessary for a meaningful
comparison between repeat laboratory testing and the
utilisation of other health services. Generic clinical request
systems have the potential to help clinicians screen for
inappropriate, ineffective, potentially dangerous, or unneces-
sary tests.
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